Skip to main content
Clinical Trials/NCT01560390
NCT01560390
Completed
Phase 4

Use of Ketamine Associate With an Opioid for Sedation in ICU : a Randomized Controlled Double Blind Study

University Hospital, Clermont-Ferrand1 site in 1 country164 target enrollmentOctober 2011

Overview

Phase
Phase 4
Intervention
Rémifentamil + KETAMINE
Conditions
Sedation for Mechanical Ventilation
Sponsor
University Hospital, Clermont-Ferrand
Enrollment
164
Locations
1
Primary Endpoint
Amount of opiate used between study enrollment and mechanical ventilation withdrawal.
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

The aim of the study is to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.

Detailed Description

All consecutive mechanically ventilated patients admitted in the intensive care unit (ICU)will be randomized to receive an infusion of 0.15 mg/kg/h of kétamine or placebo. Nurses and physicians will be blinded of the allocation arm. The infusion of ketamine will be stopped as soon as remifentanil will be discontinued by the physician.

Registry
clinicaltrials.gov
Start Date
October 2011
End Date
August 2012
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University Hospital, Clermont-Ferrand
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • all patients under mechanical ventilation

Exclusion Criteria

  • psychotic
  • chronic use of opiates
  • age \< 18 years

Arms & Interventions

Rémifentanil + Kétamine

to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.

Intervention: Rémifentamil + KETAMINE

Rémifentanil + Kétamine

to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.

Intervention: ketamine

Rémifentanil + Placebo

to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.

Intervention: Rémifentamil + KETAMINE

Rémifentanil + Placebo

to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.

Intervention: ketamine

Outcomes

Primary Outcomes

Amount of opiate used between study enrollment and mechanical ventilation withdrawal.

Time Frame: after 24 hours

Secondary Outcomes

  • Confusion Duration assessed by CAM-ICU(after 24 hours)
  • mechanical ventilation duration(after 24 hours)
  • ICU length of stay(after 24 hours)
  • Mortality at D28(at day 28)
  • hyperalgesia during sedation(after 24 hours)

Study Sites (1)

Loading locations...

Similar Trials